Mucoadhesive Pullulan Capsules for Vaginal Antiprogestin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antiprogestin treatments, particularly when administered orally, face limitations such as poor chronic administration efficacy and systemic side effects, making them less ideal for hormone-dependent disorders.
Innovation Solution
Mucoadhesive capsules comprising pullulan and a capsule fill formulation with a selective progesterone receptor modulator or antiprogestin, designed for vaginal delivery, which adheres to the vaginal mucosa for sustained release, minimizing systemic exposure and maximizing local drug concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiprogestins are administered orally, then systemic delivery is achieved, but systemic side effects increase and chronic administration efficacy decreases
Solution Approach 1:
The patent introduces the vaginal mucosa as an intermediary delivery route between oral administration and direct local action. The mucoadhesive capsule adheres to the vaginal mucosa, allowing the antiprogestin to be absorbed locally and enter the bloodstream at lower systemic concentrations, thereby reducing side effects while maintaining therapeutic efficacy for hormone-dependent disorders
Solution Approach 2:
The invention employs mucoadhesive materials that provide localized action at the vaginal mucosa. The capsule is designed to adhere specifically to the vaginal wall, creating a localized reservoir that releases the drug slowly at the absorption site, improving chronic administration efficacy while minimizing systemic exposure
2Reliability
If higher doses are used to achieve therapeutic levels, then treatment efficacy improves, but systemic concentrations increase and side effects worsen
Solution Approach 1:
The patent changes the administration route parameter from oral to vaginal, which fundamentally alters the pharmacokinetic profile. This route change allows achieving therapeutic efficacy at lower doses because the drug is absorbed directly from the vaginal mucosa into the systemic circulation, bypassing first-pass metabolism and reducing the required dose while minimizing side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mucoadhesive capsules provide effective, sustained delivery of antiprogestins to the vaginal mucosa, reducing systemic concentrations and minimizing side effects, while achieving therapeutic levels for conditions like endometriosis and uterine fibroids with lower doses compared to oral administration.
Implementation Method 1
mucoadhesive capsules comprising pullulan
Implementation Method 2
for delivering the active agent to the vaginal mucosa
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule comprising one or more antiprogestins.